Table 2.
IFN-α species | Molecular characteristics | Doses | Advantages vs conventional formulation |
---|---|---|---|
Pegylated IFN-α-2a (Pegasys) | 40-kDa branched polyethylene glycol (PEG) | 450-μg weekly administration | Allows protracted tumour cell exposure |
Improves patient compliance | |||
Reduces toxicity | |||
Pegylated IFN-α-2b (Peg-Intron A) | 12-kDa monomethoxy PEG | 7.5 μg/kg weekly administration | Allows protracted tumour cell exposure |
Improves patient compliance | |||
Reduces toxicity |